For the 203 chief executive officers in BioWorld's company survey who received base salary plus bonus Rank Executive Company Name Salary ($k) Bonus ($k) Total ($k) 1 Kevin W. Sharer AMGEN INC 1,562 3,875 5,437 2 James C. Mullen BIOGEN IDEC INC 1,192 2,400 3,592 3 Henri A. Termeer GENZYME CORP 1,579 1,963 3,541 4 Sol J. Barer CELGENE CORP 1,101 2,167 3,268 5 Gregory T. Lucier LIFE TECHNOLOGIES CORP 978 2,050 3,028 6 Frank Baldino Jr. CEPHALON INC 1,245

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options* ($k) Stocks* ($k) AASTROM BIOSCIENCES Gerald D. Brennan 240 20 259 27 131 417 0 0 ACADIA PHARMA Thomas H. Aasen1 302 0 302 12 120 435 125 0 ACCELRYS Rick E. Russo2 275 105 380 14 215 609 0 72 ACCESS PHARMA Stephen B. Thompson 154 0 154 8 137 299 0 0 ACHILLION PHARMA Mary Kay Fenton 210 38 248 7 195 449 2 0 ACORDA THERAPEUTICS

For the 187 chief financial officers in BioWorld's company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 Robert A. Bradway AMGEN INC 798 1,200 1,998 2 Paul J. Clancy BIOGEN IDEC INC 492 1,143 1,636 3 Michael S. Wyzga GENZYME CORP 510 490 999 4 David F. Hoffmeister LIFE TECHNOLOGIES CORP 475 445 921 5 David W. Gryska CELGENE CORP 530 351 881 6 J. Kevin Buchi CEPHALON INC 540 340 880 7 B. Lynne

For the 92 chief operating officers in BioWorld's company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 Michael Walsh CYPRESS BIOSCIENCE INC 300 1,747 2,047 2 Jerry E. Corbin INTEGRA LIFESCIENCES HLDGS 227 1,572 1,799 3 Gordon G. Pugh ALKERMES INC 353 1,080 1,434 4 Yakov Kogan CLEVELAND BIOLABS INC 218 1,100 1,318 5 John F. Milligan GILEAD SCIENCES INC 728 442 1,170 6 Marc S. Hanover GTX INC 435 694

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options* ($k) Stocks* ($k) ACHILLION PHARMA Gautam Shah 265 61 326 16 526 868 AFFYMAX Robert F. Venteicher 314 59 373 4 629 1006 ALEXION PHARMA David W. Keiser1 400 400 15 270 684 5947 248 ALEXZA PHARMACTCLS Michael J. Simms 315 88 403 18 390 811 ALKERMES Gordon G. Pugh 353 1080 1434 73 1956 3463 62 57 ALLOS THERAPEUTICS James V. Caruso

For the 159 research and development executives BioWorld's company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 Roger M. Perlmutter AMGEN 915 1,220 2,135 2 Norbert W. Bischofberger GILEAD SCIENCES 654 495 1,149 3 Ivan D. Horak ENZON PHARMACEUTICALS 534 320 854 4 Peter Mueller VERTEX PHARMACEUTICALS 457 385 842 5 David M. Goldenberg IMMUNOMEDICS 500 225 725 6 Joel McComb ILLUMINA 447 238 684 7

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options* ($k) Stocks* ($k) ACADIA PHARMA Roger Mills 361 0 361 1 206 568 0 0 ACCELRYS Mathew A. Hahn1 208 68 276 10 245 532 0 48 ACCESS PHARMA David P. Nowotnik 254 0 254 12 137 403 0 0 ACHILLION PHARMA Elizabeth Olek2 240 68 308 6 46 360 0 0 ACORDA THERAPEUTICS Andrew R. Blight 295 112 407 7 671 1,085 1,534 175 ACUSPHERE Howard

For the 78 legal officers in BioWorld's company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 Gil M. Labrucherie NEKTAR THERAPEUTICS 380 482 862 2 Gregg H. Alton GILEAD SCIENCES INC 493 298 791 3 Kenneth S. Boger VERTEX PHARMACEUTICALS INC 398 315 714 4 Thomas I.H. Dubin ALEXION PHARMACEUTICALS INC 300 315 615 5 James H. Davis HUMAN GENOME SCIENCES INC 434 175 609 6 Philip H. Moise IMMUCOR INC 450

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options* ($k) Stocks* ($k) ACCELRYS David R. Mersten1 265 0 265 0 0 265 0 94 ACORDA THERAPEUTICS Jane Wasman 325 0 325 4 52 380 90 277 ACUSPHERE Dennis Bucceri 275 160 435 10 223 668 0 0 AFFYMETRIX Barbara A. Caulfield2 572 0 572 8 204 784 0 50 ALEXION PHARMA Thomas I.H. Dubin 300 90 390 5 588 983 0 358 ALLOS THERAPEUTICS Marc H

For the 83 business & corporate development executives in BioWorld's company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 Paul Mahon UNITED THERAPEUTICS CORP 608 294 902 2 Kurt C. Graves VERTEX PHARMACEUTICALS INC 456 370 826 3 Barry A. Labinger HUMAN GENOME SCIENCES INC 475 190 665 4 Adelene Q. Perkins INFINITY PHARMACEUTICALS, INC. 390 195 585 5 Gustav Christensen DYAX CORP 374 200 574 6 Tristan B

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options* ($k) Stocks* ($k) ACADIA PHARMA John Kaiser 277 111 388 80 90 558 0 0 ACCELRYS Richard C. G. Murphy1 299 15 315 425 62 802 0 58 ACCESS PHARMA Phillip S. Wise 200 0 200 10 137 347 0 0 AFFYMAX Paul B. Cleveland 334 122 456 4 636 1,095 0 0 ALEXZA PHARMA Anthony G. Tebbut2 321 46 367 76 314 757 0 0 ALLOS THERAPEUTICS James V

Rank Executive Company Bonus ($k) Salary ($k) Bonus As Percentage Of Salary Other ($k) Recent Stock Price Stock Price 12/31/2008 Percent Change In Stock 1 Kevin W. Sharer AMGEN 3,875 1,562 248.1 531 60.92 57.75 5.5 2 James C. Mullen BIOGEN IDEC 2,400 1,192 201.3 354 48.98 47.63 2.8 3 Sol J. Barer CELGENE CORP 2,167 1,101 196.8 217 54.64 55.28 -1.2 4 Gregory T. Lucier LIFE TECH CORP 2,050 978 209.5 64 43.4 23.31 86.2 5 Henri A. Termeer

CEOs Whose Total Direct Compensation Exceeded $1 Million Executive Company Salary ($k) Bonus ($k) Other ($k) Long-Term ($k) Total Direct ($k) Aart Brouwer CELGENE CORP 463 745 52 0 1,260 Anna E. Gluskin GENEREX BIOTECHNOLOGY CORP 515 215 289 151 1,169 Armando Anido AUXILIUM PHARMA 500 341 12 1,487 2,340 Carolyn J. Logan SALIX PHARMACEUTICALS LTD 713 321 14 255 1,303 Catherine M. Burzik KINETIC CONCEPTS 834 714 7 344 1,899 Christopher Clement

Rank Executive Company Salary ($k) Salary Prior FY ($k) Percent Change in Salary Recent Stock Price Stock Price 12/31/08 Percent Change in Stock Market Capitalization ($M) 1 Henri A. Termeer GENZYME CORP 1,579 1,504 5 52.78 66.37 -20.5 14,238 2 Kevin W. Sharer AMGEN 1,562 1,547 0.9 60.92 57.75 5.5 61,590 3 Frank Baldino Jr. CEPHALON 1,245 1,197 4 56.99 77.04 -26 3,923 4 James C. Mullen BIOGEN IDEC 1,192 1,142 4.4 48.98 47.63 2.8 14,148

1. Represents a company 401(K) plan matching contribution of $7,560 and group term life insurance premiums of $784 paid on behalf of Mersten. 2. Effective June 13, 2008, Caulfield resigned as executive vice president and general counsel. Her compensation for 2008 reflects this partial year of service. 3. Douglas' employment agreement was effective as of May 31, 2005 and continues through May 31, 2009. Douglas' annual base salary was $215,000 as of Dec. 31, 2008. 4. Other compensation includes

* Options and stocks columns indicate value realized on exercise of options and on vesting of restricted stocks, respectively. 1. Keiser retired as the company's president and CEO as of Dec. 31, 2008. 2. Other compensation includes $14,334 of 401(k) employer match which began on Jan. 1, 2008, and $3,437 for health insurance premiums. 3. Regan's employment with the company terminated effective Sept. 2, 2008. 4. Dr. Bennett resigned from the company effective June 13, 2008. 5. On March 30

* Options and stocks columns indicate value realized on exercise of options and on vesting of restricted stocks, respectively. 1. Other compensation represents a company 401(K) plan matching contribution of $9,520 and group term life insurance premiums of $883 paid on behalf of Hahn. 2. Other compensation represents $281 of life insurance premiums paid by Achillion and $5,262 in matching company contributions pursuant to Achillion's 401(k) defined contribution plan. 3. Bonus represents cash

* Options and stocks columns indicate value realized on exercise of options and on vesting of restricted stocks, respectively. 1. Other compensation includes $11,500, $11,250 and $11,000 in employer 401(k) matching and $840, $855 and $840 of supplemental life insurance premium payments in each of 2008, 2007 and 2006, respectively. 2. Other compensation represents a company 401(K) plan matching contribution of $1,563 and group term life insurance premiums of $1,161 paid on behalf of Russo. 3

* Options and stocks columns indicate value realized on exercise of options and on vesting of restricted stocks, respectively. 1. Mark J. Emkjer is listed as former president/CEO. Other compensation to Emkjer represents a company 401(K) plan matching contribution of $7,935 and group term life insurance premiums of $2,760 paid on behalf of Emkjer. A company 401(K) plan matching contribution of $16,500, a vacation benefit payout of $49,531, group term life insurance premiums of $2,286 paid on